# Cytotoxic Effects of Sorafenib, Lapatinib, and Bevacizumab, Alone and in Combination, on Medullary Thyroid Carcinoma Cells

## TL;DR

This study explores drug combinations to treat medullary thyroid cancer, finding that combining certain drugs with Bevacizumab improves effectiveness and reduces needed doses.

## Contribution

The study introduces a novel combination therapy using Sorafenib, Lapatinib, and Bevacizumab for medullary thyroid carcinoma.

## Key findings

- Sorafenib and Lapatinib showed strong cytotoxic effects on medullary thyroid cancer cells.
- Combining these drugs with Bevacizumab significantly enhanced their effectiveness at lower doses.
- The Lapatinib–Bevacizumab combination was most potent in inhibiting cell viability.

## Abstract

Thyroid cancer is one of the most common endocrine cancers, and medullary thyroid carcinoma is a rare but aggressive type that can be difficult to treat. Surgery is often the first option, but many patients eventually need drug treatments. Current medicines, called tyrosine kinase inhibitors, can slow the disease but often cause severe side effects and drug resistance. In this study, we tested the effects of two kinase inhibitors, Sorafenib and Lapatinib, alone and in combination with Bevacizumab, an antibody that blocks blood vessel growth in tumors. We found that Sorafenib and Lapatinib were effective against medullary thyroid cancer cells, and when combined with Bevacizumab their effects were much stronger, even at lower doses. These findings suggest that combination therapy may be a promising way to improve treatment while reducing side effects, and they could guide future research into better strategies for patients with this challenging cancer.

Background: Medullary thyroid carcinoma is a rare neuroendocrine tumor with limited therapeutic options, as current kinase inhibitors are often associated with significant toxicity and drug resistance. This study aimed to explore novel treatment strategies by testing targeted agents alone and in combination. Methods: Human medullary thyroid carcinoma TT cells with RET mutations were treated with Sorafenib, Lapatinib, and Bevacizumab. Cell proliferation was monitored in real time using the xCELLigence system, and apoptosis was assessed by flow cytometry. Results: Sorafenib and Lapatinib each showed strong, dose-dependent cytotoxic effects, with Lapatinib demonstrating the greatest potency. Bevacizumab alone exhibited minimal cytotoxic activity, but when combined with Sorafenib or Lapatinib it significantly enhanced their effects, even at concentrations that were only partially effective individually. The Lapatinib–Bevacizumab combination produced the most potent inhibition of cell viability, comparable to high-dose monotherapy. Conclusions: These findings suggest that combining kinase inhibitors with Bevacizumab may enhance antitumor activity, allow the use of lower drug doses, and overcome resistance, representing a promising therapeutic strategy for medullary thyroid carcinoma that warrants further investigation in clinical settings.